[1] Vanhecke TE, Kim R, Raheem SZ,etal. Myocardial isch-emia in patientswith diastolic dysfunction and heart failure [J]. Curr Cardiol Rep, 2010,12:216-222. [2] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelinesfor the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the Eu-ropean Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [J]. Eur J Heart Fail, 2016,18(8):891-975. [3] Goodwill AG, Frisbee SJ, Stapleton PA,et al. Impact of chronic anticholesterol therapy on development of microvas-cular rarefaction in the metabolic syndrome [J]. Microcircu-lation, 2009,16:667-684. [4] Ulus T, Parspour A, Cavusoglu Y,et al. Statins improve myocardial perfusion in metabolic syndrome patients who have perfusion defects on myocardial perfusion imaging and angiographically normal coronary arteries [J]. Eur Rev Med Pharmacol Sci,16:328-334. [5] Sucato V, Novo G, Evola S,et al. Coronary microvascu-lar dysfunction in patients with diabetes, hypertension and metabolic syndrome [J]. Int J Cardiol,2015,186:96-97. [6] Mohammed SF, Hussain S, Mirzoyev SA,et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction [J]. Circulation, 2015,131(6):550-559.